Genmab — April 2021
-
Og det er selvfølgelig denne opstilling jeg ref. til: https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/92301_Genmab_sales_estimates_revision._5.pdf
-
Teclistamab's clinical trial application accepted by CDE/ China https://med.sina.com/article_detail_103_2_98280.html
-
Johnson & Johnson BCMA / CD3 dobbelt antistofanvendelse til klinisk anvendelse
Kilde: Medicinsk Rubiks terning 2021-04-01 A- A +
Den 1. april viste CDE's officielle websted, at anvendelsen af Johnson & Johnsons BCMA / CD3 bispecifikt antistof Teclistamab-injektion (acceptnummer: JXSL2101002 / 3) blev accepteret af CDE. -
God morgen.

-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/92535_Genmab_sales_estimates_rev._6.pdf her opdateret salgsestimat skema i gode danske kroner. Der er regnet med usd kurs 6 - peak sale for EPCO nok lidt for aggresivt men og vi kender ikke udgifter - Jan sagde på Q&A at det var for tidligt at estimere evt. profit
-
Doublo. Det er Epcoritamab som skal rykke Genmab over de 3000 så det hele afhænger af kommende data vil jeg tro - der er virklig mange penge til Genmab hvis Epcoritamab kommer på markedet og kursen burde rykker over 4000 hvis/når salget af Epco begynder at rykke
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind